Mr. Michal Efraty reports

NEUROTHERA LABS- CLEARMIND MEDICINE COLLABORATION LEADS TO PATENT APPLICATION FOR DEPRESSION THERAPY

Neurothera Labs Inc. partner Clearmind Medicine Inc. has filed a patent application with the Intellectual Property Department in Hong Kong, China, for an innovative combination therapy designed to treat major depressive disorder (MDD).

This innovative treatment combines Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) sourced by Neurothera.

The patent filing underscores the promise of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression, a condition affecting more than 332 million people globally, according to the World Health Organization article titled "Depressive Disorder (Depression)," published in August, 2025. Given the anticipated mechanism of action, this therapy could provide a more accessible, safer and affordable alternative to existing antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and other conventional options.

About Neurothera Labs Inc.

Neurothera Labs s a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.

We seek Safe Harbor.